<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="77306">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01958645</url>
  </required_header>
  <id_info>
    <org_study_id>D5050C00001</org_study_id>
    <nct_id>NCT01958645</nct_id>
  </id_info>
  <brief_title>To Assess Safety, Tolerability and Pharmacodynamics of Intravenous MEDI8111 After Single Ascending Doses.</brief_title>
  <official_title>A Phase I, Single-blind, Randomised, Placebo-controlled, Single Centre Study to Investigate the Safety, Tolerability and Pharmacodynamics of Intravenous MEDI8111 After Single Ascending Doses in Healthy Male Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AstraZeneca</source>
  <oversight_info>
    <authority>United Kingdom: Medicines and Healthcare product Regulatory Agency</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A study to investigate the safety, tolerability and pharmacodynamics of MEDI8111 after
      single ascending doses in healthy male.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A phase I, single-blind, randomised, placebo-controlled, single centre study to investigate
      the safety, tolerability and pharmacodynamics of intravenous MEDI8111 after single ascending
      doses in healthy male subjects.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>November 2013</start_date>
  <completion_date type="Anticipated">October 2014</completion_date>
  <primary_completion_date type="Anticipated">October 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science</study_design>
  <primary_outcome>
    <measure>Description of the safety profile in terms of adverse events (AE),vital signs, ECG, telemetry, lab variables, immunogenicity and physical examination</measure>
    <time_frame>From screening and up to the lab follow-up visit (Day 29)</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Description of the pharmacodynamic (PD) profile in terms of endogenous thrombin potential (ETP)</measure>
    <time_frame>At screening, Days 1-5 and clinical follow-up (Day 15)</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Description of the PD profile in terms of prothrombin time (PT) , activated partial thrombin time (aPTT), fibrinogen, prothrombin fragment 1 + 2, d-dimer, thrombin anti-thrombin complex (TAT)</measure>
    <time_frame>At screening, Day -1, Days 1-5, 7, clinical follow-up (Day 15) and lab follow-up (Days 22 and 29)</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Description of the pharmacokinetic (PK) profile in terms of Factor II plasma concentrations (measured by 3 assay methods:Factor (F) II antigen assay, prothrombinase assay and FII clot assay)</measure>
    <time_frame>Screening, Day -1, -30 min before inf, 0 h, 20 min, 40 min, 59 min, 62-65 min, 1.25 h, 1.5 h, 2h, 3h, 4h, 8h, 12h, 24h, 36h, 48h, 72h, 96h, 144h after start of inf, clinical follow up (Day 15) and lab follow up (Days 22 and 29)</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">48</enrollment>
  <condition>Healthy Subjects</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>MEDI8111</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo for MEDI8111</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MEDI8111</intervention_name>
    <description>MEDI8111 lyophilisate for solution for infusion</description>
    <arm_group_label>A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo for MEDI8111 saline solution for infusion</description>
    <arm_group_label>B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Provision of signed and dated, written informed consent prior to any study specific
             procedures, Healthy male subjects aged 18-40 years with suitable veins for
             cannulation or repeated venepuncture, Have a body mass index (BMI) between 18 and 30
             kg/m2 inclusive and weight at least 50 kg an no more than 100 kg inclusive, Male
             subjects should be willing to avoid fathering a child by either true abstinence or
             the use of two effective means of contraception from the day of dosing until 3 months
             after dosing with the IP. They should also be willing to use barrier methods from the
             day of dosing until 3 months after dosing.

        Exclusion Criteria:

          -  Prothrombotic mutation such as factor V Leiden, or deficiencies of protein C, protein
             S, prothrombin, antithrombin or APC, Antibodies to coagulation FII, History or family
             history of venous or arterial thromboembolic event, and/or myocardial infarction
             before age of 50 years, ETP level at baseline &gt;2000nM/min, FII level (by clot) at
             screening and/or at baseline outside 50-250% of the normal range
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Karin Wahlander, MD</last_name>
    <role>Study Director</role>
    <affiliation>AstraZeneca Mölndal, Sweden</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Anders Berggren, MD</last_name>
    <role>Study Chair</role>
    <affiliation>AstraZeneca Mölndal, Sweden</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Timothy Mant, Prof</last_name>
    <role>Principal Investigator</role>
    <affiliation>Quintiles London, United Kingdom</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Quintiles London (QLON) London England Quiniles London (QLON) London England</last_name>
    <phone>+44 0 800 634 11 32</phone>
    <email>ClinicalTrialTransparency@astrazeneca.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>May 2014</verification_date>
  <lastchanged_date>May 7, 2014</lastchanged_date>
  <firstreceived_date>October 7, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Phase 1, healthy male subjects, safety and tolerability, pharmacodynamic, pharmacokinetic</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
